Tag: neuroendocrine tumors
![pfizer logo1](https://www.carcinoid.org/wp-content/uploads/2011/05/pfizer-logo1.jpeg)
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE![Pfizer logo](https://www.carcinoid.org/wp-content/uploads/2011/05/pfizer-logo.jpeg)
Breaking News: FDA Approves Pfizer’s Sutent for Pancreatic NET Cancer Patients
The US Food and Drug Administration today announced approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to …
READ MORE![Novartis logo](https://www.carcinoid.org/wp-content/uploads/2011/05/novartis-logo.gif)
Breaking News: FDA Approves Treatment for pNET Patients
For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients! The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients. This is a milestone for the carcinoid/NET…
READ MORE![Multidisciplinary Team at Bad Berka](https://www.carcinoid.org/wp-content/uploads/2011/04/multidisciplinary-team-at-bad-berka1.jpg)
1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT)
Since 1997, when he first used the radiolabeled peptide Y-90 DOTATOC (a somatostatin analogue) to treat a 15-year-old boy with a rare neuroendocrine tumor, called paraganglioma, and saw the boy go from being wheelchair-bound and in terrible pain to …
READ MORE![FDA logo](https://www.carcinoid.org/wp-content/uploads/2011/03/fda-logo.png)
Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting
Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …
READ MORE![dsc2397 copyw outshadowsharp1](https://www.carcinoid.org/wp-content/uploads/2011/03/dsc2397-copyw_outshadowsharp1.jpg)
Carcinoid Cancer Foundation Symposium Features Leading NET Cancer Specialists & a Patient Panel
What are the most state-of-the-art treatments for carcinoid and NET cancer patients today? Join us on May 1st when the Carcinoid Cancer Foundation presents its 14th Annual Symposium, “Neuroendocrine Tumor Management: The Era of Personalized…
READ MORE![healthy body healthy mind](https://www.carcinoid.org/wp-content/uploads/2011/02/healthy-body-healthy-mind.jpg)
Neuroendocrine Tumors Featured on Healthy Body, Healthy Mind Television Series
For a comprehensive overview of neuroendocrine tumors, watch this fascinating video on the Healthy Body, Healthy Mind television series. Every episode on the health and wellness TV series focuses on the stories of real people; people who are working…
READ MORE![webmd logo1](https://www.carcinoid.org/wp-content/uploads/2011/01/webmd-logo1.gif)
WebMD Articles Raise Awareness about Carcinoid Cancer
Understanding carcinoid tumors, carcinoid syndrome, and treatments for carcinoid when surgery is not an option are the focus of three feature articles by Ellen Greenlaw on WebMD.com this month. For these articles, Ms. Greenlaw sought the expertise…
READ MORE![Steve Jobs Talks about Liver Transplant](https://www.carcinoid.org/wp-content/uploads/2011/01/steve-jobs-talks-about-liver-transplant.jpg)
Steve Jobs to Take New Medical Leave from Apple
Steve Jobs, CEO and co-founder of Apple and the most well-known member of the carcinoid and neuroendocrine tumor community, is taking a new medical leave of absence. This announcement was reported today, January 17, 2011, by The New York Times, a year…
READ MORE![staff sergeant daniel barber helicopter](https://www.carcinoid.org/wp-content/uploads/2010/09/staff-sergeant-daniel-barber-helicopter.jpg)
A Carcinoid Soldier’s Survivor Story
When Staff Sergeant Daniel Barber of D Company 1-106th AVN in the Missouri National Guard was first diagnosed with carcinoid cancer in 2009 he experienced feelings of shock, despair, anger, fear and frustration. But he was also relieved because he knew…
READ MORE